Decision makes Wegovy the first GLP-1 class therapy cleared for MASH, a liver condition that affects around 5 per cent of ...

Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.

Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

Denmark’s Novo Nordisk scored a significant regulatory win for GLP-1 drug Wegovy (semaglutide), as the US Food and Drug ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a new indication for Wegovy® ...

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver ...

Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form of liver disease, beating rival Eli Lilly & Co. to the US market for the ...

The Phase 3 clinical trial found that Wegovy reduced inflammation and scarring in people with metabolic dysfunction-associated steatohepatitis, or MASH.

The Phase 3 clinical trial found that Wegovy reduced inflammation and scarring in people with metabolic dysfunction-associated steatohepatitis, or MASH.

The trial, funded by drugmaker Novo Nordisk, included 800 patients with MASH from 37 countries. Patients either got a weekly 2.4 milligram dose of semaglutide, the active ingredient in Ozempic and ...